Cell and gene therapy industry continues to expand manufacturing infrastructure in the UK
London, United Kingdom, [20th November 2024]: The Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation committed to the advancement of cell and gene therapies has released its Good Manufacturing Practice (GMP) Report 2024. It highlights continued growth in manufacturing infrastructure for advanced therapies, with 32 MHRA-licensed GMP manufacturing facilities in the UK, an increase from 28 last year.
To access the report Manufacturing Report 2024 – Email
Read the full news following this link. Published on the 20th of november 2024.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (11 février 2025). Cell and gene therapy industry continues to expand manufacturing infrastructure in the UK. ELSIBI. Consulté le 18 mars 2025 à l’adresse https://doi.org/10.58079/13axi